OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BIOMARIN PHARMACEUTICAL Share Price

Certificat

DE000SV36DV7

Delayed Deutsche Boerse AG 20:42:49 28/05/2024 BST
4.01 EUR +5.53% Intraday chart for OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - BIOMARIN PHARMACEUTICAL
1 month+12.09%
3 months+55.10%
Date Price Change
28/05/24 4.01 +5.53%
27/05/24 3.8 -2.31%
24/05/24 3.89 0.00%
23/05/24 3.89 +1.83%
22/05/24 3.82 +1.87%

Delayed Quote Deutsche Boerse AG

Last update May 28, 2024 at 08:42 pm

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellPUT
Underlying BIOMARIN PHARMACEUTICAL INC.
IssuerLogo Issuer Société Générale Société Générale
WKN SV36DV
ISINDE000SV36DV7
Date issued 18/04/2023
Strike 117.8 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.64
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.01
Lowest since issue 1.58
Spread 0.01
Spread %0.25%

Company Profile

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
-
More about the company

Ratings for BioMarin Pharmaceutical Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: BioMarin Pharmaceutical Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
75.52 USD
Average target price
109.3 USD
Spread / Average Target
+44.76%
Consensus